cervical cancerHPV DNA integrationprognosisclinical outcomeThe presence of virus DNA integration into the cell genome was studied for 47 primary HPV16-positive patients with morphologically verified stage III cervical cancer. By using ROC analysis, the patients were divided into two groups: with and ...
The Company announced five-year results from the final pre-specified overall survival (OS) analysis of a Phase 3 trial, which evaluated Libtayo (cemiplimab) monotherapy versus chemotherapy as a first-line treatment for certain adults with advanced non-small cell lung cancer (NSCLC) with ≥50% ...
a humanized monoclonal antibody targeting programmed cell death receptor-1 (PD-1), in non-small cell lung cancer (NSCLC),Incyteanticipates sharing the full dataset at an upcoming medical meeting in the fourth quarter of 2024.
Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis At 10 years, the cross-over strategy yielded absolute disease-free survival rates of 83.7% and 67.6% for node-negative and node-positive patients, ... RS Punglia,KM Kuntz,EP Winer,...
("CEO") effectiveNovember 1, 2024.Dr. Fuhas served as the Company's Interim CEO sinceJuly 15, 2024.Dr. Fuwill continue to serve as a member of the I-Mab Board of Directors.Dr. Fuhas over 20 years of experience in the life sciences industry, leading and developing clinical-stage ...
GAAP and non-GAAP R&D expenses increased in the third quarter of 2024, compared to the third quarter of 2023, driven by the advancement of the Company's clinical pipeline, including late-stage oncology programs, and higher headcount and headcount-related costs. Acquired IPR&D ...
“We secured FDA approval and launched Optune Lua for the treatment of patients with metastatic non-small cell lung cancer, achieved significant year-over-year revenue growth across our major markets, and solidified our management team to drive our next stage of growth. It is an exciting time ...
Cervical biopsy confirmed the diagnosis of cervical cancer, but unfortunately, the disease had progressed to an advanced stage, precluding surgical intervention. While the patient and her family expressed a desire to continue the pregnancy, conservative treatment for her condition was unsuccessful, with ...
CStone announced long-term survival data for sugemalimab in combination with platinum-based chemotherapy as first-line treatment of stage IV NSCLC at theEuropean Society for Medical Oncology (ESMO) Congress2024. Four-year follow-up data showed that sugemalimab plus platinum-based chemother...
Create Portfolio Manage My Portfolio Portfolio Health Check Privacy Alert Preferences Subscriptions Premium & Pro About Premium Group Subscriptions Alpha Picks About Alpha Picks FREE Newsletters Investing Groups Learn About Investing Groups Most Popular Free Trials Top Rated Dividend Investing Value Investing...